Shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) dropped 8.2% on Thursday . The stock traded as low as $8.20 and last traded at $8.24. Approximately 8,339,503 shares were traded during trading, an increase of 39% from the average daily volume of 5,988,080 shares. The stock had previously closed at $8.98.

ENDP has been the topic of several research analyst reports. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. Mizuho reiterated a “buy” rating and set a $14.00 price target (down previously from $19.00) on shares of Endo International PLC in a research note on Tuesday, September 12th. William Blair reiterated a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Zacks Investment Research downgraded Endo International PLC from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, ValuEngine downgraded Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the stock. Endo International PLC presently has an average rating of “Hold” and an average price target of $12.64.

The stock has a 50-day moving average price of $8.70 and a 200 day moving average price of $10.59. The firm’s market cap is $1.84 billion.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same quarter in the previous year, the company earned $0.86 EPS. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. Analysts forecast that Endo International PLC will post $3.52 EPS for the current fiscal year.

In other news, COO Terrance J. Coughlin purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were acquired at an average price of $7.70 per share, with a total value of $154,000.00. Following the purchase, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Blaise Coleman purchased 6,500 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were purchased at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the purchase, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The disclosure for this purchase can be found here. Insiders have bought a total of 36,000 shares of company stock worth $279,460 in the last three months. Corporate insiders own 0.50% of the company’s stock.

A number of hedge funds have recently bought and sold shares of ENDP. Diamond Hill Capital Management Inc. purchased a new stake in Endo International PLC in the 2nd quarter valued at approximately $5,454,000. Ameriprise Financial Inc. lifted its stake in Endo International PLC by 685.0% in the 1st quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares in the last quarter. American International Group Inc. lifted its stake in Endo International PLC by 451.5% in the 1st quarter. American International Group Inc. now owns 396,887 shares of the company’s stock valued at $4,429,000 after buying an additional 324,922 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in Endo International PLC by 93.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock valued at $6,314,000 after buying an additional 273,024 shares in the last quarter. Finally, Sivik Global Healthcare LLC purchased a new stake in Endo International PLC in the 2nd quarter valued at approximately $2,793,000. 90.71% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/10/12/endo-international-plc-endp-trading-down-8-2.html.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.